🟢 Teva Pharma is trading 4.15% up today after direct NYSE trading began

Teva Pharma is trading 4.15% up at $38.63 after ordinary shares began direct NYSE trading on September 14, 2026, replacing the ADS structure one-for-one.

• The transition improves direct investor access and coincides with management’s September 14 Barclays presentation, highlighting accelerating growth products, biosimilars, stronger credit metrics, and progress toward long-term targets.
• Healthcare strength supports shares as major U.S. indexes trade lower; the listing is the clearest company-specific catalyst. Confidence is medium: news and price align, but attribution is unconfirmed.